Imukin ( DrugBank: - )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
18脊髄小脳変性症(多系統萎縮症を除く。)2
58肥大型心筋症1
228閉塞性細気管支炎1

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002432-40-IT
(EUCTR)
03/03/201627/05/2021Safety and Efficacy of yIFN treatment in Friedreich ataxiaSafety and Efficacy of yIFN treatment in Friedreich ataxia - ¿IFN in Friedreich Ataxia FRDA is a progressive neurodegenerative disease inherited as recessive trait. It manifests itself usually in adolescence and affects various systems including the central and peripheral nervous system (balance, coordination, speech and sensitivity), the heart with hypertrophic cardiomyopathy, the bones with skeletal deformities (scoliosis, claw foot) and in some cases diabetes mellitus. The disease causes severe and progressive disability, significantly reducing the life expectancy of patients.
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: IMUKIN - 6 FLACONI 0.5 ML 100 MCG
Product Name: Imukin
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEANULLNot RecruitingFemale: yes
Male: yes
12Phase 2Italy
2EUCTR2012-001881-14-IT
(EUCTR)
01/03/201311/01/2013A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patientsA phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patients - GIFT/1 Friedreich's Ataxia
MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: IMUKIN*SC 6F 0,5ML 100MCG
INN or Proposed INN: INTERFERON GAMMA-1B
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Italy

58. 肥大型心筋症


臨床試験数 : 119 薬物数 : 165 - (DrugBank : 45) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 161
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002432-40-IT
(EUCTR)
03/03/201627/05/2021Safety and Efficacy of yIFN treatment in Friedreich ataxiaSafety and Efficacy of yIFN treatment in Friedreich ataxia - ¿IFN in Friedreich Ataxia FRDA is a progressive neurodegenerative disease inherited as recessive trait. It manifests itself usually in adolescence and affects various systems including the central and peripheral nervous system (balance, coordination, speech and sensitivity), the heart with hypertrophic cardiomyopathy, the bones with skeletal deformities (scoliosis, claw foot) and in some cases diabetes mellitus. The disease causes severe and progressive disability, significantly reducing the life expectancy of patients.
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: IMUKIN - 6 FLACONI 0.5 ML 100 MCG
Product Name: Imukin
ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEANULLNot RecruitingFemale: yes
Male: yes
12Phase 2Italy

228. 閉塞性細気管支炎


臨床試験数 : 96 薬物数 : 125 - (DrugBank : 34) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 155
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022467-36-DE
(EUCTR)
22/06/2011A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapyA phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapy steroid-refractory bronchiolitis obliterans
MedDRA version: 13.1;Level: PT;Classification code 10029888;Term: Obliterative bronchiolitis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Imukin
Product Name: Imukin
INN or Proposed INN: Interferon gamma-1b
Other descriptive name: INTERFERON GAMMA-1B
Freistaat BayernNULLNot RecruitingFemale: yes
Male: yes
Phase 2Germany